NCT06715462 - Efficacy and Safety of the N0750 Compared to Monotherapies in the Treatment of Painful Diabetic Peripheral Neuropathy | Biotech Hunter

Enrollment

666

Participants

Timeline

Start Date

April 30, 2026

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2028

Conditions

Painful Diabetic Peripheral Neuropathy (PDPN)

Interventions

DRUG

N0750

N0750 caps + Cymbalta placebo caps + Lyrica placebo caps

DRUG

Cymbalta®

Cymbalta® caps + N0750 placebo caps + Lyrica placebo caps

DRUG

Lyrica®

Lyrica® caps + N0750 placebo caps + Cymbalta placebo caps

Trial Locations (1)

Eurofarma Laboratórios S.A, Itapevi